Skip to main content
. 2022 Jun 6;27(8):646–654. doi: 10.1093/oncolo/oyac089

Figure 3.

Figure 3.

(A) Kaplan-Meier analysis of progression-free survival comparing CDK4/6i combinations with visceral vs. non-visceral disease. (B) Kaplan-Meier analysis of progression-free survival comparing CDK 4/6i combinations with de novo and recurrent metastatic presentation. Top panel: pooled analysis; middle panel: for aromatase inhibitor combinations; Bottom panel for fulvestrant combinations.